Calciumantagonisten bei Nierenerkrankungen

  • E. Ritz
  • S. R. Orth

Zusammenfassung

Bei nierengesunden hypertensiven Patienten führen Calciumantagonisten zu einem Anstieg der Nierendurchblutung; dasselbe wird bei Patienten mit vorbestehender Nierenschädigung beobachtet. Ferner verhindern Calciumantagonisten in einigen, aber nicht allen Nierenschädigungsmodellen der Ratte das spontane Auftreten einer Glomerulosklerose, ohne Glomerulusvolumen und Kapillardurchmesser zu beeinflussen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Aguas AP, Nickerson PA (1983) Effect of verapamil on blood pressure and lesions in heart and kidney of rats made hypertensive by deoxycorticosterone (DOC). Am J Pathol 110:48–54PubMedGoogle Scholar
  2. 2.
    Alivizatos PA, Maxa J, Lucio S, Chen J (1993) The immunosuppressive qualities of calcium channel blockers. Transplantation 56:1604PubMedCrossRefGoogle Scholar
  3. 3.
    Alvarez A, Martul E, Veiga F, Forteza J (1994) Functional, histologic, and ultrastructural study of the protective effects of verapamil in experimental ischemic acute renal failure in the rabbit. Ren Fail 16:193–207PubMedCrossRefGoogle Scholar
  4. 4.
    Anderson S (1991) Renal hemodynamic effects of calcium channel antagonists in rats with reduced renal mass. Hypertension 17:288–295PubMedGoogle Scholar
  5. 5.
    Ar’Rajab A, Dawidson IJA, Harris RB, Mileski WJ, Sentementes JT (1994) Deleterious effect of cyclosporines on the ischemic kidney in the rat and the protection by the calcium antagonist verapamil. J Am Soc Nephrol 5:93–101PubMedGoogle Scholar
  6. 6.
    Bakris GL (1990) Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 112:701–702Google Scholar
  7. 7.
    Bakris GL (1991) Renal effects of calcium antagonists in diabetes mellitus. An overview of studies in animal models and in humans. Am J Hypertens 4:487S–493SPubMedGoogle Scholar
  8. 8.
    Bakris GL, Barnhill BW, Sadler R (1992) Treatment of arterial hypertension in diabetic humans:importance of therapeutic selection. Kidney Int 41:912–919PubMedCrossRefGoogle Scholar
  9. 9.
    Bakris GL, Burnett JC (1985) A role for calcium in radiocontrast-induced reductions in renal hemodynamics. Kidney Int 27:465–468PubMedCrossRefGoogle Scholar
  10. 10.
    Barbosa LM, Gauthier VJ, Davis CL (1995) Bone pain that responds to calcium channel blockers. A retrospective and prospective study of transplant recipients. Transplantation 59:541–544PubMedGoogle Scholar
  11. 11.
    Barros EJG, Boim MA, Ajzen H, Ramos OL, Schor N (1987) Glomerular hemodynamics and hormonal participation on cyclosporine nephrotoxicity. Kidney Int 32:19–25PubMedCrossRefGoogle Scholar
  12. 121986.
    Bennett WM () Comparison of cyclosporine nephrotoxicity with aminoglycoside nephrotoxicity. Clin Nephrol 25 (suppl. 1): S126–S129Google Scholar
  13. 13.
    Blackshear JL, Garnic D, Williams GH (1987) Exaggerated renal vasodilator response to calcium entry blockade in first-degree relatives of essential hypertensive subjects. Hypertension 9:384–389PubMedGoogle Scholar
  14. 14.
    Brazy PC, Fitzwilliam JF (1990) Progressive renal disease: Role of race and antihypertensive medications. Kidney Int 37:1113–1119PubMedCrossRefGoogle Scholar
  15. 15.
    Brunner FP, Block HA, Hermle M, Thiel G, Mihatsch MJ (1991) Control of hypertension by verapamil enhances renal damage in a rat remnant kidney model. Nephrol Dial Transplant 6:420–427PubMedGoogle Scholar
  16. 16.
    Burke TJ, Arnold PE, Gordon JA, Bulger RE, Dobyan DC, Schreier RW (1984) Protective effect of intrarenal calcium membrane blockers before and after renal ischemia. J Clin Invest 74:1830–1841PubMedCrossRefGoogle Scholar
  17. 17.
    Byrd L, Shermann RL (1979) Radiocontrast-induced renal failure. Medicine 58:270–279PubMedCrossRefGoogle Scholar
  18. 18.
    Caldicott WJH, Hollemberg NK, Abrams HL (1970) Characteristics of response of renal vascular bed to contrast medium. Invest Radiol 5:539–547PubMedCrossRefGoogle Scholar
  19. 19.
    Carmines PK, Navar LG (1989) Disparate effects of Ca channel blockade on afferent and efferent arteriolar response to ANG II. Am J Physiol 256:F1015–F1020PubMedGoogle Scholar
  20. 20.
    Casellas D, Navar LG (1984) In vitro perfusion of juxtamedullary nephrons in rats. Am J Physiol 246:F349–F358PubMedGoogle Scholar
  21. 21.
    Chitwood KK, Heim-Duthoy KL (1993) Immunosuppressive properties of calcium channel blockers. Pharmacotherapy 13:447–454PubMedGoogle Scholar
  22. 22.
    Coggins CH, Fang LS-T (1988) Acute renal failure associated with antibiotics, anesthetic agents, and radiographic contrast agents. In: Brenner BM, Lazarus JM (eds) Acute renal failure. WB Saunders Co, Philadelphia, p 295Google Scholar
  23. 23.
    Cohen DJ, Teng SN, Appel GB (1994) Influence of oral felodipine on serum cyclosporine concentrations. Clin Transplant 8:541–545PubMedGoogle Scholar
  24. 24.
    Crocker JF, Renton KW, LeVatte TL, McLellan DH (1994) The interaction of the calcium channel blockers verapamil and nifedipine with cyclosporin A in pediatric renal transplant patients. Pediatr Nephrol 8:408–411PubMedCrossRefGoogle Scholar
  25. 25.
    Dawidson I, Rooth P, Fry WR, Sandor Z, Willms C, Coorpender L, Alway C, Reisch J (1989) Prevention of acute cyclosporine-induced renal blood flow inhibition and improved immunosuppression with verapamil. Transplantation 48:575–580PubMedGoogle Scholar
  26. 26.
    Dumont L, Chen H, Daloze P, Xu D, Garceau D (1993) Immunosuppressive properties of the benzothiazepine calcium antagonists diltiazem and clentiazem, with and without cyclosporine, in heterotopic rat heart transplantation. Transplantation 56:181–184PubMedCrossRefGoogle Scholar
  27. 27.
    Dworkin LD (1991) Effects of calcium antagonists on glomerular hemodynamics and structure in experimental hypertension. Am J Kid Dis 17 (suppl. 1): 89–93PubMedGoogle Scholar
  28. 28.
    Dworkin LD, Benstein JA, Parker M, Tolbert E, Feiner HD (1993) Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int 43:808–814PubMedCrossRefGoogle Scholar
  29. 29.
    Dworkin LD, Feiner HD, Parker M, Tolbert E (1991) Effects of nifedipine and enalapril on glomerular structure and function in uninephrectomized SHR. Kidney Int 39:1112–1117PubMedCrossRefGoogle Scholar
  30. 30.
    Dworkin LD, Levin RI, Benstein JA, Parker M, Ullian ME, Kim Y, Feiner HD (1990) Effects of nifedipine and enalapril on glomerular injury in rats with deoxycorticosteronesalt hypertension. Am J Physiol 259:F598–F604PubMedGoogle Scholar
  31. 31.
    Eliahou HE, Cohen D, Hellberg B, Ben-David A, Herzog D, Schechter P, Kapuler S, Kogan N (1988) Effect of the calcium channel blocker nisoldipine on the progression of chronic renal failure in man. Am J Nephrol 8:285–290PubMedCrossRefGoogle Scholar
  32. 32.
    Epstein M, Loutzenhiser R (1990) Potential applicability of calcium antagonists as renal protective agents. In: Epstein M, Loutzenhiser R (eds) Calcium antagonists and the kidney. Hanley & Belfus, Inc., Philadelphia, pp 275–298Google Scholar
  33. 33.
    Farber JL (1981) The role of calcium in cell death. Life Sci 29:1289–1295PubMedCrossRefGoogle Scholar
  34. 34.
    Feehally J, Walls J, Mistry N, Horsburgh T, Taylor J, Veitch PS, Bell PR (1987) Does nifedipine ameliorate cyclosporin A nephrotoxicity? Br Med J 295:310CrossRefGoogle Scholar
  35. 35.
    Ferder L, Daccordi H, Martello M, Panzalis M, Inserra F (1992) Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients. Hypertension 19 (suppl. 2): II237–II242PubMedGoogle Scholar
  36. 36.
    Ferguson CJ, Hillis AN, Williams JD, Griffin PJ, Salaman JR (1990) Calcium channel blokkers and other factors influencing delayed function in renal allografts. Nephrol Dial Transplant 5:816–820PubMedGoogle Scholar
  37. 37.
    Fleming JT, Garthoff B, Mayer D, Rosen B, Steinhausen M (1987) Comparison of the effect of antihypertensive drugs on pre-and postglomerular vessels of the hydronephrotic kidney. J Cardiovasc Pharmacol 10 (suppl.10): S149–S153PubMedGoogle Scholar
  38. 38.
    Fleming JT, Parekh N, Steinhausen M (1987) Calcium antagonists preferentially dilate preglomerular vessels of hydronephrotic kidney. Am J Physiol 253:F1157–F1163PubMedGoogle Scholar
  39. 39.
    Frei U, Harms A, Bakovich-Alt R, Pichlmayr R, Koch KM (1990) Calcium channel blokkers for kidney protection. J Cardiovasc Pharmacol 16 (suppl. 6):S11–515PubMedGoogle Scholar
  40. 40.
    Fry WR, Dawidson I, Alway CC, Rooth P (1988) Cyclosporine A induces decreased blood flow in cadaveric kidney transplants. Transplant Proc 20 (suppl. 3): 222–225PubMedGoogle Scholar
  41. 41.
    Gecim IE, Christmas SE, Brew R, King A, McDicken I, Sells RA, Bakran A (1993) The relationship between calcium antagonist therapy and growth of T lymphocytes from human renal allograft biopsies. Transplantation 56:1015–1016PubMedGoogle Scholar
  42. 42.
    Giuliano RA, Paulus GJ, Verpooten GA, Pattyn VM, Pollet DE, Nouwen EJ, Laurent G, Carlier M-B, Maldague P, Tulkens PM, De Broe ME (1984) Recovery of cortical phospholipidosis and necrosis after acute gentamicin loading in rats. Kidney Int 26:838–847PubMedCrossRefGoogle Scholar
  43. 43.
    Goldfarb D, Iaina A, Elinbov ME (1985) Beneficial effect of verapamil in ischemic acute renal failure in the rat. Proc Soc Exp Biol Med 172:389–392Google Scholar
  44. 44.
    Goligorsky MS, Chaimovitz C, Rapoport J, Goldstein J, Kol R (1985) Calcium metabolism in uremic nephrocalcinosis:Preventive effect of verapamil. Kidney Int 27:774–779PubMedCrossRefGoogle Scholar
  45. 45.
    Grekas D, Alivanis P, Kalekou H, Papayianni K, Karamouzis M, Tourkantonis A (1992) Acute cyclosporin A renal dysfunction in dogs reversed by calcium antagonists and antiplatelet agents. Ren Fail 14:493–498PubMedCrossRefGoogle Scholar
  46. 46.
    Griffin KA, Picken M, Bidani AK (1994) Radiotelemetric BP monitoring, antihypertensives and glomeruloprotection in remnant kidney model. Kidney Int 46:1010–1018PubMedCrossRefGoogle Scholar
  47. 47.
    Haag-Weber M, Hörl WH (1994) Effect of calcium channel blockers on intracellular calcium accumulation. Nephrol Dial Transplant 9 (suppl. 3): 24–27PubMedGoogle Scholar
  48. 48.
    Harris DCH, Hammond WS, Burke TJ, Schrier RW (1987) Verapamil protects against progression of experimental chronic renal failure. Kidney Int 31:41–46PubMedCrossRefGoogle Scholar
  49. 49.
    Hauser AC, Derfler K, Stockenhuber F, Wamser P, Marosi L, Balcke P (1991) Effect of calcium-channel blockers on renal function in renal-graft recipients treated with cyclosporine. N Engl J Med 324:1517PubMedGoogle Scholar
  50. 50.
    Hayashi K, Epstein M, Loutzenhiser R (1989) Pressure-induced vasoconstriction of renal microvessels in normotensive and hypertensive rats. Studies in the isolated perfused hydronephrotic kidney. Circ Res 65:1475–1484PubMedGoogle Scholar
  51. 51.
    Holdaas H, Hartmann A, Lien MG, Nilsen L, Jervell J, Fauchald P, Endresen L, Dj’seland O, Berg KJ (1991) Contrasting effects of lisinopril and nifedipine on albuminuria and tubular transport functions in insulin dependent diabetics with nephropathy. J Int Med 229:163–170CrossRefGoogle Scholar
  52. 52.
    Hostetter TH (1995) Progression of renal disease and renal hypertrophy. Annu Rev Physiol 57:263–278PubMedCrossRefGoogle Scholar
  53. 53.
    Hostetter TH, Brenner BM (1988) Renal circulatory and nephron function in experimental acute renal failure. In: Brenner BM, Lazarus JM (eds) Acute renal failure. WB Saunders Co, Philadelphia, 67Google Scholar
  54. 54.
    Howard RL, Shapiro JI, Babcock S, Chan L (1990) The effect of calcium channel blockers on the cyclosporine dose requirement in renal transplant recipients. Ren Fail 12:89–92PubMedCrossRefGoogle Scholar
  55. 55.
    Humes HD, Weinberg JM, Knauss TC (1982) Clinical and pathophysiologic aspects of aminoglycoside nephrotoxicity. Am J Kid Dis 2:5–29PubMedGoogle Scholar
  56. 56.
    Iaina A, Herzog D, Cohen D, Gavendo S, Kapuler S, Serban I, Schiby G, Eliahou HE (1986) Calcium entry-blockade with verapamil in cyclosporin A plus ischemia induced acute renal failure in rats. Clin Nephrol 25 (suppl. 1):S168–5170PubMedGoogle Scholar
  57. 57.
    Ichikawa I, Miele JF, Brenner BM (1979) Reversal of renal cortical actions of angiotensin II by verapamil and manganese. Kidney Int 16:137–147PubMedCrossRefGoogle Scholar
  58. 58.
    Idée J-M, Santus R, Beaufils H, Balut C, Huntsman AM, Bourbouze R, Koeltz B, Jouanneau C, Bonnemain B (1995) Comparative effects of low-and high-osmolar contrast media on the renal function during early degenerative gentamicin-induced nephropathy in rats. Am J Nephrol 15:66–74PubMedCrossRefGoogle Scholar
  59. 59.
    Irzyniec T, Mall G, Greber D, Ritz E (1992) Beneficial effect of nifedipine and moxonidine on glomerulosclerosis in spontaneously hypertensive rats. A micromorphometric study. Am J Hypertens 5:437–443PubMedGoogle Scholar
  60. 60.
    Ishikawa I, Hollenberg NK (1976) Pharmacologic interruption of the renin-angiotensin system in myohemoglobinuric acute renal failure. Kidney Int 10 (suppl. 6): 5183–5190Google Scholar
  61. 61.
    Jackson B, Johnston CI (1988) The contribution of systemic hypertension to progression of chronic renal failure in the remnant kidney: effect of treatment with an angiotensin converting enzyme inhibitor or a calcium inhibitor. J Hypertens 6:495–501PubMedCrossRefGoogle Scholar
  62. 62.
    Jarusiripipat C, Chan L, Shapiro JI, Schrier RW (1992) Effect of long-acting calcium entry blocker (anipamil) on blood pressure, renal function and survival of uremic rats. J Pharmacol Exp Ther 260:243–247PubMedGoogle Scholar
  63. 63.
    Keown PA, Stiller CR, Wallace AC (1985) The nephrotoxicity of cyclosporine. In: Williams GM, Burdick JF, Solez K (eds) Kidney transplantation rejection: current issues in diagnosis and treatment. Dekker, New York, 431Google Scholar
  64. 64.
    Kiyama S, Nanishi F, Tomooka S, Okuda S, Onoyama K, Fujishima M (1994) Inhibitory effects of antihypertensive drugs on mesangial cell proliferation after anti-thymocyte serum (ATS)-induced mesangiolysis in spontaneously hypertensive rats. Life Sci 54:1891–1900PubMedCrossRefGoogle Scholar
  65. 65.
    Kloke HJ, Wetzels JFM, van Hamersvelt HW, Koene RAP, Kleinbloesem CH, Huysmans, M. (1990) Effects of nitrendipine and cilazapril on renal hemodynamics and albuminuria in hypertensive patients with chronic renal failure. J Cardiovasc Pharmacol 16:924–930PubMedCrossRefGoogle Scholar
  66. 66.
    Klotman PE, Boatman JE, Volpp BD, Baker JD, Yarger WE (1985) Captopril enhances aminoglycoside nephrotoxicity in potassium-depleted rats. Kidney Int 28:118–127PubMedCrossRefGoogle Scholar
  67. 67.
    Kltitsch K, Schmidt P, Großwendt J (1972) Der Einfluß von Bay a 1040 auf die Nierenfunktion des Hypertonikers. Arzneimittelforsch 22:377–380Google Scholar
  68. 68.
    Larson TS, Hudson K, Mertz JI, Romero JC, Knox FG (1983) Renal vasoconstrictive response to contrast medium. J Lab Clin Med 102:385–391Google Scholar
  69. 69.
    Lee SM, Hillman BJ, Clark RL, Michael UF (1985) The effects of diltiazem and captopril on glycerol-induced acute renal failure in the rat. Invest Radiol 20:961–970PubMedCrossRefGoogle Scholar
  70. 70.
    Lee SM, Michael UF (1985) The protective effect of nitrendipine on gentamicin acute renal failure in rats. Exp Mol Pathol 43:107–114PubMedCrossRefGoogle Scholar
  71. 71.
    Leonetti G, Cuspidi C, Sampieri L (1982) Comparison of cardiovascular, renal and humeral effects of acute administration of two calcium channel blockers in normotensive and hypertensive subjects. J Cardiovasc Pharmacol 4: S319–S324PubMedCrossRefGoogle Scholar
  72. 72.
    Lortholary O, Blanchet F, Nochy D, Heudes D, Seta N, Amirault P, Carbon C (1993) Effects of diltiazem on netilmicin-induced nephrotoxicity in rabbits. Antimicrob Agents Che-mother 37:1790–1798Google Scholar
  73. 73.
    Loutzenhiser R, Epstein M (1987) Modification of the renal hemodynamic response to vasoconstrictors by calcium antagonists. Am J Nephrol 7 (suppl 1):7–16PubMedCrossRefGoogle Scholar
  74. 74.
    Loutzenhiser R, Epstein M, Horton C (1987) Modification by dihydropyridine type calcium antagonists of the renal hemodynamic response to vasoconstrictors. J Cardiovasc Pharmacol 9 (suppl 1):S70—S75PubMedGoogle Scholar
  75. 75.
    Loutzenhiser RD, Epstein M (1987) Renal hemodynamic effects of calcium antagonists. Am J Med 82:23–28PubMedCrossRefGoogle Scholar
  76. 76.
    Loutzenhiser R, Epstein M (1985) Effects of calcium antagonists on renal hemodynamics. Am J Physiol 249:F616—F629Google Scholar
  77. 77.
    Lumlertgul D, Wongmekiat O, Sirivanichai C, Hundagoon P, Keoplung M, Conger JD, Schrier RW (1991) Intrarenal infusion of gallopamil in acute renal failure. A preliminary report. Drugs 42 (suppl. 1):44–50PubMedCrossRefGoogle Scholar
  78. 78.
    Malis CD, Cheung JY, Leaf A, Bonventre JV (1983) Effects of verapamil in models of ischemic acute renal failure in the rat. Am J Physiol 245:F735–F742PubMedGoogle Scholar
  79. 79.
    Mandreoli M, Esposti ED, Cocchi R, Fabbri A, Guerrini L, Fusaroli M (1990) Do calcium channel blockers have any influence on the immunological status of renal graft recipients on ciclosporin therapy? Am J Nephrol 10:58–60PubMedCrossRefGoogle Scholar
  80. 80.
    Marx M, Weber M, Merkel F, Meyer zum Buschenfelde KH, Kohler H (1990) Additive effects of calcium antagonists on cyclosporin A-induced inhibition of T-cell proliferation. Nephrol Dial Transplant 5:1038–1044PubMedGoogle Scholar
  81. 81.
    Melbourne Diabetic Nephropathy Study Group (1991) Comparison between perindopril and nifedipine in hypertensive and normotensive patients with microalbuminuria. Br Med J 302:210–216CrossRefGoogle Scholar
  82. 82.
    Mills S, Chan L, Schwertschlag U, Shapiro JI, Schrier RW (1987) The protective effect of (—) emopamil on renal function following warm and cold ischemia. Transplantation 43:928–940PubMedGoogle Scholar
  83. 83.
    Mimran A, Insua A, Ribstein J, Bringer J, Monnier L (1988) Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. Diabetes Care 11:850–853PubMedCrossRefGoogle Scholar
  84. 84.
    Mimran A, Insua A, Ribstein J, Monnier L (1988) Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. Diabetes Care 11:850–853PubMedCrossRefGoogle Scholar
  85. 85.
    Montanan A, Vallisa D, Ragni G, Guerra A, Colla R, Novarini A, Coruzzi P (1988) Abnormal renal response to calcium entry blockade in normotensive offspring of hypertensive parents. Hypertension 12:498–505Google Scholar
  86. 86.
    Morgan T, Anderson A (1988) Interaction of slow-channel calcium blocking drugs with sodium restriction, diuretics and angiotensin converting enzyme inhibitors. J Hypertens 6 (suppl. 4): S652–S654Google Scholar
  87. 87.
    Murray BM, Paller MS (1986) Beneficial effects of renal denervation and prazosin on GFR and renal blood flow after cyclosporine in rats. Clin Nephrol 25 (suppl. 1): S37–S39PubMedGoogle Scholar
  88. 88.
    Minter K, Hergenröder S (1994) The combination of verapamil with trandolapril shows a nephroprotective effect in hypertensive rats (SHRSP). J Hypertens 12 (suppl. 3): 114aGoogle Scholar
  89. 89.
    Navar LG, Champion WJ, Thomas CE (1986) Effects of calcium channel blockade on renal vascular resistance responses to changes in perfusion pressure and angiotensin-converting enzyme inhibition in dogs. Circ Res 58:874–881PubMedGoogle Scholar
  90. 90.
    Neumayer H-H, Junge W, Küfner A, Wenning A (1989) Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: A prospective randomized clinical trial. Nephrol Dial Transplant 4:1030–1036PubMedGoogle Scholar
  91. 91.
    Neumayer H-H, Kunzendorf U, Schreiber M (1992) Protective effects of calcium antagonists in human renal transplantation. Kidney Int 41 (suppl. 36): S87–S93Google Scholar
  92. 92.
    Nichols C, Amann K, Törnig J, Zeier M, Mall G, Ritz E (1994) Differential effects of anti-hypertensive treatment on the development of glomerulosclerosis in subtotally nephrectomized rats. J Am Soc Nephrol 5:790aGoogle Scholar
  93. 93.
    Orth S, Nowicki M, Wiecek A, Ritz E (1993) Nephroprotective effect of ACE inhibitors. Drugs 46 (suppl. 2):189–196PubMedCrossRefGoogle Scholar
  94. 94.
    Orth SR, Nobiling R, Bönisch S, Ritz, E (1995) Effect of calcium channel blockers on human mesangial cell growth: Evidence for actions independent of L-type Ca’ channels. Kidney Int (im Druck)Google Scholar
  95. 95.
    Orth SR, Weinreich T, Bönisch S, Weih M, Ritz E (1995) Angiotensin II induces hypertrophy and hyperplasia in adult human mesangial cells. Exp Nephrol 3:23–33PubMedGoogle Scholar
  96. 96.
    Palter MS, Greene EL (1994) Role of calcium in reperfusion injury of the kidney. Ann NY Acad Sci 723:59–70CrossRefGoogle Scholar
  97. 97.
    Palmer BF, Dawidson I, Sagalowski A, Sandor Z, Lu CY (1991) Improved outcome of cadaveric renal transplantation due to calcium channel blockers. Transplantation 52:640–645PubMedCrossRefGoogle Scholar
  98. 98.
    Papadimitriou M, Alexopoulos E, Vargemezis V, Sakellariou G, Kosmidou I, Metaxas P (1983) The effect of preventive administration of verapamil on acute ischaemic renal failure in dogs. Proc Eur Dial Transplant Assoc 20:650–655PubMedGoogle Scholar
  99. 99.
    Perico N, Amuchastegui CS, Malanchini B, Bertani T, Remuzzi G (1994) Angiotensinconverting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late renal structural damage. Exp Nephrol 2:220–228PubMedGoogle Scholar
  100. 100.
    Perico N, Benigni A, Zoja C, Delaini F, Remuzzi G (1986) Functional significance of exaggerated renal thromboxane A2 synthesis induced by cyclosporin A. Am J Physiol 251: F581—F587PubMedGoogle Scholar
  101. 101.
    Petric R, Freeman D, Wallace C, McDonald J, Stiller C, Keown P (1988) Effect of cyclosporine on urinary prostanoid excretion, renal blood flow, and glomerulotubular function. Transplantation 45:883–889PubMedCrossRefGoogle Scholar
  102. 102.
    Petric R, Freeman D, Wallace C, McDonald J, Stiller C, Keown P (1990) Modulation of experimental cyclosporine nephrotoxicity by inhibition of thromboxane synthesis. Transplantation 50:558–563PubMedCrossRefGoogle Scholar
  103. 103.
    Pirsch JD, D’Alessandro AM, Roecker EB, Knechtle SJ, Reed A, Sollinger HW, Kalayoglu M, Belzer FO (1993) A controlled, double-blind, randomized trial of verapamil and cyclosporine in cadaver renal transplant patients. Am J Kid Dis 21:189–195PubMedGoogle Scholar
  104. 104.
    Podjarny E, Rathaus M, Shapira J, Kariv N, Pomeranz A, Zadok S, Bernheim J (1990) Captopril, but not diltiazem, favorably affects the course of early chronic renal disease in rats. Nephron 55:196–202PubMedCrossRefGoogle Scholar
  105. 105.
    Rabelink TJ, Kaasjager KA, Boer P, Stroes EG, Braam B, Koomans HA (1994) Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology. Kidney Int 46:376–381PubMedCrossRefGoogle Scholar
  106. 106.
    Raij L, Keane WF (1985) Glomerular mesangium: Its function and relationship to angiotensin II. Am J Med 79:24–30PubMedCrossRefGoogle Scholar
  107. 107.
    Reams GP, Villarreal D, Wu Z, Wang X, Luger AM, Bauer JH (1993) An evaluation of the renal protective effect of manidipine in the uninephrectomized spontaneously hypertensive rat. Am Heart J 125:620–625PubMedCrossRefGoogle Scholar
  108. 108.
    Rooth P, Dawidson I, Diller K, Täljedal I-B (1988) Protection against cyclosporine-induced impairment of renal microcirculation by verapamil in mice. Transplantation 45:433–437PubMedCrossRefGoogle Scholar
  109. 109.
    Rose UM, Bindels RJ, Jansen JW, vanOs CH (1994) Effects of Ca’ channel blockers, low Ca’ medium and glycine on cell Ca’ and injury in anoxic rabbit proximal tubules. Kidney Int 46:223–229PubMedCrossRefGoogle Scholar
  110. 110.
    Roth M, Keul R, Emmons LR, Hörl WH, Block LH (1992) Manidipine regulates the transcription of cytokine genes. Proc Natl Acad Sci USA 89:4071–4075PubMedCrossRefGoogle Scholar
  111. 111.
    Ruggenenti P, Perico N, Mosconi L, Gaspari F, Benigni A, Amuchastegui CS, Bruzzi I, Remuzzi G (1993) Calcium channel blockers protect transplant patients from cyclosporineinduced daily renal hypoperfusion. Kidney Int 43:706–711PubMedCrossRefGoogle Scholar
  112. 112.
    Russo D, Testa A, Della Volpe L, Sansone G (1990) Randomised prospective study on renal effects of two different contrast media in humans: Protective role of a calcium channel blocker. Nephron 55:254–257PubMedCrossRefGoogle Scholar
  113. 113.
    Sakurai T, Kurita T, Nagano S, Sonoda T (1972) Antihypertensive vasodilating and sodium diuretic actions of D-cis isomer of benzothiazepine derivative (CRD-401). Acta Urol Jpn 18:695–701Google Scholar
  114. 114.
    Salvetti A, Innocenti PF, Iardella M, Pambianco F, Saba GC, Rossetti M, Botta GF (1987) Captopril and nifedipine interactions in the treatment of essential hypertensives: a crossover study. J Hypertens 5 (suppl.): S139—S142CrossRefGoogle Scholar
  115. 115.
    Schrier RW, Arnold PE, Van Putten VJ, Burke TJ (1987) Cellular calcium in ischemic acute renal failure. Kidney Int 32:313–321PubMedCrossRefGoogle Scholar
  116. 116.
    Schwertschlag U, Schrier RW, Wilson P (1986) Beneficial effects of calcium channel blokkers and calmodulin binding drugs on in vitro renal cell anoxia. J Pharmacol Exp Ther 238:119–124PubMedGoogle Scholar
  117. 117.
    Shapiro JI, Cheung C, Itabashi A, Chan L, Schrier RW (1985) The effect of verapamil on renal function after warm and cold ischemia in the isolated perfused rat kidney. Transplantation 40:596–600PubMedCrossRefGoogle Scholar
  118. 118.
    Sherwood T, Lavender JP (1969) Does renal blood flow rise or fall in response to diatrizoate? Invest Radiol 4:327–334PubMedCrossRefGoogle Scholar
  119. 119.
    Shimizu T, Kawabata T, Nakamura M (1990) Protective effect of a novel calcium blocker, S-312-d, on ischemic acute renal failure in rat. J Pharmacol Exp Ther 255:484–490PubMedGoogle Scholar
  120. 120.
    Shirahase H, Uehara Y, Wada K, Shimaji H, Ishimitsu T, Hashizume Y, Kanda M, Nakamura S (1994) Protective effect of the calcium antagonist NKY-722 in Dahl salt-sensitive rats. J Hypertens 12:137–144PubMedCrossRefGoogle Scholar
  121. 121.
    Shudo C, Masuda Y, Sugita H, Tanaka S, Tornita K (1994) Effects of efonidipine hydrochloride (NZ-105), a new calcium antagonist, against acute renal failure in rats. Gen Pharmacol 25:1451–1458PubMedCrossRefGoogle Scholar
  122. 122.
    Shultz PJ, Raij L (1990) Inhibition of human mesangial cell proliferation by calcium channel blockers. Hypertension 15 (suppl. I): I-764–80Google Scholar
  123. 123.
    Siegl H, Ryffel B, Petric R, Shoemaker P, Muller A, Donatsch P, Mihatsch M (1983) Cyclosporine, the renin-angiotensin-aldosterone system and renal adverse reactions. Transplant Proc 15 (suppl. 1):2719–2725Google Scholar
  124. 124.
    Sketris IS, Methot ME, Nicol D, Belitsky P, Knox MG (1994) Effect of calcium channel blockers on cyclosporine clearance and use in renal transplant patients. Ann Pharmacother 28:1227–1231PubMedGoogle Scholar
  125. 125.
    Sluiter HE, Wetzels JFM, Huysmans FTM, Koene RAP (1987) The natriuretic effect of the dihydropyridine calcium antagonist felodipine: A placebo-controlled study involving intravenous angiotensin II in normotensive volunteers. J Cardiovasc Pharmacol 10 (suppl. 10):S154–S161PubMedGoogle Scholar
  126. Steele TH, Challoner-Hue L (1985) Glomerular response to verapamil by isolated spontaneously hypertensive rat kidney. Am J Physiol 248:F668—F673Google Scholar
  127. 127.
    Steele TH, Challoner-Hue L (1987) Response of isolated Dahl rat kidney to calcium antagonists. Kidney Int 31:941–945PubMedCrossRefGoogle Scholar
  128. 128.
    Stefanski A, Amann K, Ritz E (1995) To prevent progression: ACE inhibitors, calcium antagonists or both? Nephrol Dial Transplant 10:151–153PubMedGoogle Scholar
  129. 129.
    Steinhausen M, Snoei H, Parekh N, Baker R, Johnson PC (1983) Hydronephrosis: a new method to visualize vas afference, efference, and glomerular network. Kidney lnt 23:794–806CrossRefGoogle Scholar
  130. 130.
    Sterzel RB, McKenzie DE (1987) Effects of nitrendipine on the course of experimental immunologic glomerulonephritis. J Cardiovasc Pharmacol 9 (suppl. 1): S60–S64PubMedGoogle Scholar
  131. 131.
    Stornello M, Valvo EV, Scapellato L (1989) Hemodynamic, renal, and humoral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor captopril in hypertensive type II diabetic patients with nephropathy. J Cardiovasc Pharmacol 14:851–855PubMedCrossRefGoogle Scholar
  132. 132.
    Sumpio B, Baue AE, Chaudry IH (1987) Treatment with verapamil and adenosine triphosphate-MgC12 reduces cyclosporine nephrotoxicity. Surgery 101:315–322Google Scholar
  133. 133.
    Sunderrajan S, Reams G, Bauer J (1986) Renal effects of diltiazem in primary hypertension. Hypertension 8:238–242PubMedGoogle Scholar
  134. 134.
    Suthanthiran M, Haschemeyer RH, Riggio RR, Adubor C, Friedman GS, Cheigh JS, Wang JC, Fotino M, Stubenbord WT, Saal SD, Stenzel KH, Rubin AL (1993) Excellent outcome with a calcium channel blocker—supplemented immunosuppressive regimen in cadaveric renal transplantation. A potential strategy to avoid antibody induction protocols. Transplantation 55:1008–1013PubMedCrossRefGoogle Scholar
  135. 135.
    Tolins JP, Raij L (1991) Chronic amphotericin B nephrotoxicity in the rat: protective effect of calcium channel blockade. J Am Soc Nephrol 2:98–102PubMedGoogle Scholar
  136. 136.
    Van Schaik BAM, Van Nistelrooy AEJ, Geyskes GG (1985) Antihypertensive and renal effects of nicardipine. J Lab Clin Med 105:498–503Google Scholar
  137. 137.
    van Zwieten PA (1993) Protective effects of calcium antagonists in different organs and tissues. Am Heart J 125:566–571PubMedCrossRefGoogle Scholar
  138. 138.
    Wagner K, Schultze M, Molzahn M, Neumayer HH (1986) The influence of long-term infusion of the calcium antagonist diltiazem on postischemic acute renal failure in conscious dogs. Klin Wschr 64:135–140PubMedCrossRefGoogle Scholar
  139. 139.
    Wait RB, White GJ, Davis JH (1983) Beneficial effect of verapamil on postischemic failure. Surgery 94:276–282PubMedGoogle Scholar
  140. 140.
    Watson AJ, Gimenez LF, Klassen DK, Stout RL, Whelton A (1987) Calcium channel blokkade in experimental aminoglycoside nephrotoxicity. J Clin Pharmacol 27:625–627PubMedGoogle Scholar
  141. 141.
    Weidmann P, Boehlen LM, de Courten M (1993) Effects of different antihypertensive drugs on human diabetic proteinuria. Nephrol Dial Transplant 8:582–584PubMedGoogle Scholar
  142. 142.
    Weir MR (1991) Therapeutic benefits of calcium channel blockers in cyclosporine-treated organ transplant recipients: blood pressure control and immunosuppression. Am J Med 90:32S–36SPubMedCrossRefGoogle Scholar
  143. 143.
    Wenzel UO, Helmchen U, Schoeppe W, Schwietzer G (1994) Combination treatment of enalapril with nitrendipine in rats with renovascular hypertension. Hypertension 23:114–122PubMedGoogle Scholar
  144. 144.
    Wenzel UO, Troschau G, Schoeppe W, Helmchen U, Schwietzer G (1992) Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension. Hypertension 20:233–241PubMedGoogle Scholar
  145. 145.
    Whitty MR, Jackson B (1988) Diabetic nephropathy in the rat: differing renal effects of an angiotensin converting enzyme inhibitor and a calcium inhibitor. Diabetes Res 8:91–96PubMedGoogle Scholar
  146. 146.
    Wight JP, Bassett AH, Le Carpentier JE, El Nahas AM (1990) Effect of treatment with enalapril, verapamil and indomethacin on compensatory renal growth in the rat. Nephrol Dial Transplant 5:777–780PubMedGoogle Scholar
  147. 147.
    Xue H, Bukoski RD, McCarron DA, Bennett WM (1987) Induction of contraction in isolated rat aorta by cyclosporine. Transplantation 43:715–718PubMedCrossRefGoogle Scholar
  148. 148.
    Yokoyama S, Kaburagi T (1983) Clinical effects of intravenous nifedipine on renal function. J Cardiovasc Pharmacol 5:67–71PubMedCrossRefGoogle Scholar
  149. 149.
    Yoshioka T, Shiraga H, Yoshida Y, Fogo A, Glick AD, Deen WM, Hoyer JR, Ichikawa I (1988) „Intact nephrons“ as the primary origin of proteinuria in chronic renal disease. Study in the rat model of subtotal nephrectomy. J Clin Invest 82:1614–1623PubMedCrossRefGoogle Scholar
  150. 150.
    Zager RA, Prior RB (1986) Gentamicin and gram-negative bacteremia: A synergism for the development of experimental nephrotoxic acute renal failure. J Clin Invest 78:196–204PubMedCrossRefGoogle Scholar
  151. 151.
    Zernig G (1990) Widening potential for Ca“ antagonists: non-L-type Ca’ channel interactions. Trends Pharmacol Sci 11:38–44PubMedCrossRefGoogle Scholar
  152. 152.
    Zucchelli P, Zuccalà A, Borghi M, Fusaroli M, Sasdelli M, Stallone C, Sanna G, Gaggi R (1992) Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 42:452–458PubMedCrossRefGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt 1996

Authors and Affiliations

  • E. Ritz
  • S. R. Orth

There are no affiliations available

Personalised recommendations